Inhalation Drug Product Development Services

Orally inhaled and nasal drug product (OINDP) development services including CMC support (NDAs/ANDAs), formulation development, GMP testing, product performance testing, stability and clinical manufacturing services for small molecules and biologics

The development of orally inhaled and nasal drug products (OINDP) is being driven by the growing potential of delivery inhaled routes of administration for local and systemic therapies which offer the benefits of formulation stability coupled with patient-friendly, effective drug delivery. A rigorous approach to formulation development,  testing, stability and CMC support are necessary to determine product efficacy, quality, safety and performance.  

With  nearly 30 years of experience in supporting our clients’ product development, we deliver formulation development, product performance testing, stability, CMC support for NDAs/ANDAs and clinical manufacturing services which are designed to provide the right information at the right time. 

Our teams of OINDP experts have extensive experience of supporting clients through the inhalation drug product development process. We provide method development and validation, inhalation product analysis, bioequivalence studies, comparator studies, device/excipient compatibility studies, Quality by Design (QbD), formulation development, clinical trials materials manufacturing and product characterisation studies.

With a dedicated ICH stability storage facility integrated with our GMP laboratory testing programs, we manage all aspects of stability study requirements such as ICH and accelerated stability studies, at every stage of a product's development from early preclinical to commercial batch stability.

With specialist capabilities in development support for inhaled biologics, our scientists deploy strategic programmes of orthogonal analytical methods which aim to fully characterise the biologic entity and to establish whether the device delivery mechanism (e.g. actuation through an inhaler) has adversely affected parameters including structure, purity (aggregation, degradation, etc) and the activity of the biologic drug in line with the ICH Q6B Guidance.

Intertek's team of expert formulation scientists has extensive experience in product development of inhaled products including all types of dry powder formulations and devices, nebulised solutions/suspensions and metered dose inhalation (pMDI) product types, as well as a range of other novel respiratory delivery systems. Our unique project management approach enables you to interact directly with our expert scientists as the development process advances.

Inhalation Product Development Experience for Product Classes:

Inhalation Drug Product Development Services:

Our inhalation product experts have been working in the inhaled and nasal fields for nearly 30 years and possess the necessary experience to help design, implement and support full development, stability and testing services which are designed to provide the right information at the right time. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards.

Need help or have a question? +44 1763 261648

Need help or have a question?

+44 1763 261648
+44 1763 261648


Intertek Inhaled Product Development Brochure

White Paper:

Formulation of Biologics for Inhaled and Nasal Delivery

Fact Sheet: